Nanotechnology-based approaches for head and neck cancer treatment

Head and neck squamous cell carcinoma (HNSCC) continues to present with a poor prognosis and limited survival gains despite advances in multimodal management. In recent years, novel therapeutic approaches such as immunotherapy, proteolysis-targeting chimeras (PROTACs), and antibody-drug conjugates (ADCs) have expanded the treatment landscape. However, significant challenges remain regarding resistance, toxicity, and patient stratification. Nanotechnology-based drug delivery systems (DDS) represent a complementary strategy with the potential to enhance efficacy and minimize adverse effects by improving solubility, stability, biodistribution, and tumor-specific accumulation of anticancer agents. In this review, we summarize the development of different DDS platforms encapsulating either cisplatin or small-molecule inhibitors, highlighting preclinical studies and clinical trials in HNSCC. A particular emphasis is placed on the distinction between passive and active targeting strategies, offering a comprehensive overview of how nanoparticle functionalization and tumor-selective delivery can further enhance therapeutic outcomes. This dual perspective underscores the translational opportunities of nanomedicine within the evolving landscape of HNSCC treatment.